DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it introduced a new high energy gamma detection probe at the Society of Surgical Oncology’s 62nd Annual Cancer Symposium currently underway at the Phoenix Convention Center in Phoenix, Arizona. The new probe is intended for the detection of high energy radioactive isotopes, such as Fludeoxyglucose F 18 (FDG), in surgical oncology procedures. The new high energy probe is compatible with all models of the Company’s neo2000® and neoprobe® GDS systems sold since January 2004.
